Trial Profile
AN OPEN-LABEL, EXTENSION (ROLLOVER)STUDY OF VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE MALIGNANCIES PREVIOUSLY ENROLLED IN AN ANTECEDENT VEMURAFENIB PROTOCOL
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Roche
- 07 Apr 2020 Status changed from active, no longer recruiting to completed.
- 06 Mar 2020 This trial has been completed in Hungary, according to European Clinical Trials Database.
- 26 Feb 2020 This trial has been completed in Belgium (Global End Date: 17 Feb 2020), according to European Clinical Trials Database record.